Actively Recruiting

MALE
NCT06783127

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

Led by Santa Chiara Hospital · Updated on 2025-02-11

3000

Participants Needed

2

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.

CONDITIONS

Official Title

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

Who Can Participate

MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • BRCA mutant metastatic castration-resistant prostate cancer patients treated with olaparib in clinical practice
Not Eligible

You will not qualify if you...

  • Patients receiving olaparib treatment as part of a clinical trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Sabrina Rossetti

Naples, Italy

Actively Recruiting

2

Orazio Caffo

Trento, Italy

Actively Recruiting

Loading map...

Research Team

O

Orazio Caffo, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here